Is IVIG Covered by Medicare? Parts B, A, D, and 2026 Costs

Yes, Medicare covers IVIG (intravenous immunoglobulin) therapy in most situations, and the question of whether IVIG is covered by Medicare usually comes down to two things: where you receive the infusion and what you’re being treated for. Part B pays for IVIG in a doctor’s office, outpatient clinic, hospital outpatient department, and, for one specific diagnosis, at home. Part A covers it during an inpatient hospital stay. Part D rarely applies, because IVIG almost always needs professional administration.

How Part B Covers IVIG

Part B is the main pathway. It pays for IVIG infusions given in a doctor’s office, outpatient clinic, or hospital outpatient department when the treatment is medically necessary, along with the supplies used during the infusion, such as IV tubing and related equipment.¹

For people with primary immune deficiency disease (PIDD), Part B also covers the IVIG drug when it’s administered at home. This home benefit came from the Medicare Modernization Act of 2003 and applies only when all three conditions are met: you have a diagnosed primary immune deficiency, the product is an approved pooled plasma derivative for treating that condition, and your doctor has determined that home administration is medically appropriate.¹ Miss any one and the claim is denied.

Home IVIG needs more than the drug itself. Medicare Part B covers home infusion equipment and supplies (pumps, IV poles, tubing, catheters) as durable medical equipment, and you pay 20% of the Medicare-approved amount after your Part B deductible.² Part B also covers the professional services that go with home infusion, including nurse visits to train you or a caregiver, teach you about side effects, and check the infusion site.³

One quirk worth knowing: the 2003 PIDD home benefit covers the drug but not the administration items and services. The separate home infusion therapy benefit and the DME benefit fill that gap. If your doctor orders home IVIG, confirm your supplier is enrolled in both programs.

Part A and Part D

Part A covers IVIG when it’s given during an inpatient hospital stay. The drug is bundled into the hospital’s payment for the stay, so you won’t see a separate charge for it, but your Part A deductible and any coinsurance for the hospitalization apply.

Part D generally does not cover IVIG when a healthcare professional administers it, because those situations fall under Part B. Part D can come into play in narrow circumstances, but most IVIG requires professional administration and stays on the Part B side.⁴

Medicare Advantage Plans

Medicare Advantage plans must cover everything Original Medicare covers, IVIG included, but how you get it works differently.⁵ You’ll usually need to use in-network providers, so verify that your infusion center or home health supplier is in your plan’s network. Many Advantage plans also require prior authorization before IVIG starts, and skipping that step can leave you with the full bill.⁶

Advantage plans typically use copayments rather than straight coinsurance, and every plan caps your annual out-of-pocket spending on Part A and Part B services, which Original Medicare does not. For a recurring, expensive therapy like IVIG, that cap can be meaningful protection.

Which Diagnoses Qualify

Medicare doesn’t cover IVIG for every condition a doctor might want to treat with it. Coverage depends on the diagnosis.

The clearest path is primary immune deficiency disease. PIDD is the only condition that qualifies for the home IVIG benefit under Part B, and coverage is governed by Local Coverage Determination L33610 and policy article A52509, which list the specific diagnosis codes that support medical necessity.¹

Medicare also has a national coverage determination for IVIG in certain autoimmune blistering diseases: pemphigus vulgaris, bullous pemphigoid, mucous membrane pemphigoid, pemphigus foliaceus, and epidermolysis bullosa acquisita. Coverage requires biopsy confirmation and applies only when the patient has failed conventional therapy, has contraindications to it, or has rapidly progressing disease. Even then, IVIG is authorized only as short-term therapy, not ongoing maintenance.⁷

Off-Label Uses

Doctors prescribe IVIG for many conditions beyond the FDA label, including certain neuropathies and myasthenia gravis. Medicare can cover these off-label uses when they’re supported by recognized medical compendia such as AHFS Drug Information, Micromedex DrugDex, or the National Comprehensive Cancer Network guidelines.⁸ The diagnosis has to appear in one of those compendia, and the dosing schedule should be backed by published literature. This is where denials happen most.

What You’ll Pay in 2026

IVIG is one of the most expensive therapies Medicare covers, and a single infusion often runs several thousand dollars depending on the product, your body weight, and dosing. The 20% Part B coinsurance can mean hundreds or thousands of dollars per treatment for patients who infuse monthly or more often.

Under Part B, you first pay the annual deductible of $283 in 2026.⁹ After that, you owe 20% of the Medicare-approved amount for the drug, administration, and related supplies. If the approved cost for one infusion is $5,000, your share is $1,000. Twelve infusions a year at that rate is $12,000 in coinsurance alone.

For the rare situation where IVIG falls under Part D, enrollees have an annual out-of-pocket cap of $2,100 in 2026, covering the deductible, copayments, and coinsurance for covered drugs but not monthly premiums.¹⁰ Part D enrollees can also use the Medicare Prescription Payment Plan to spread out-of-pocket drug costs into capped monthly installments.¹¹

Ways to Reduce Your Costs

If you have Original Medicare, a Medigap plan can cover some or all of your Part B coinsurance and deductible depending on the plan letter. For a therapy this expensive, the premium often pays for itself many times over.

In a Medicare Advantage plan, your out-of-pocket maximum limits your annual Part A and Part B spending. Check your plan’s specific cap and confirm that IVIG infusions count toward it.

Regardless of your plan, ask your provider about patient assistance programs from IVIG manufacturers. Several offer copay support or free-drug programs for Medicare beneficiaries who meet income criteria.

Documentation That Prevents Denials

Incomplete records are the leading reason IVIG claims get denied. Ask your doctor’s office to confirm the file contains:

A history and physical from the last 12 months explaining the clinical rationale for IVIG.
A written physician order no more than 30 days old specifying dose, frequency, and route.
ICD-10-CM diagnosis codes that appear on Medicare’s approved list for IVIG.
Lab and test results, such as immunoglobulin levels or infection history, that support the diagnosis.
Accurate weight in kilograms before each infusion, since dosing is calculated on a mg/kg basis.
Evidence that conventional therapies failed or are contraindicated, where the coverage rule requires it.
After the first infusion, records showing how you responded to prior treatments.¹

In a Medicare Advantage plan, you’ll likely need prior authorization before starting. Your provider sends documentation to the plan, and the plan decides before the infusion happens. Confirm this is done before your first appointment.⁶

Appealing a Denial

If Medicare or your plan denies IVIG coverage, you can appeal, and many denials are reversed once documentation gaps are corrected.

Under Original Medicare, the first step is a redetermination by the Medicare Administrative Contractor that processed your claim. You have 120 days from the date you receive your Medicare Summary Notice (presumed received five days after its date). Submit your request on CMS Form 20027 or in a letter with your name, Medicare number, the services denied, the dates of service, and why you disagree. Attach whatever supporting documentation your doctor can add. The MAC generally responds within 60 days, and if the denial stands you have 180 days to escalate to a Qualified Independent Contractor for reconsideration.¹²

If your Medicare Advantage plan denies coverage, you request a reconsideration from the plan itself within 60 days. The plan has 30 days to respond for a standard request, or 72 hours if you ask for expedited review because waiting could seriously harm your health. For IVIG, expedited review is often appropriate given the medical consequences of delaying immune therapy. If the plan upholds its denial, the case moves to an Independent Review Entity.¹³

1
Centers for Medicare & Medicaid Services. Intravenous Immune Globulin
2
Medicare.gov. Home Infusion Therapy Services, Equipment, and Supplies
3
Centers for Medicare & Medicaid Services. Home Infusion Therapy/Home IVIG Services
4
Centers for Medicare & Medicaid Services. Billing and Coding – Coverage of Intravenous Immune Globulin
5
Medicare.gov. Compare Original Medicare and Medicare Advantage
6
Medicare.gov. Understanding Medicare Advantage Plans
7
Centers for Medicare & Medicaid Services. Billing and Coding – Immune Globulin Intravenous (IVIg)
8
Centers for Medicare & Medicaid Services. Billing and Coding – Off-Label Use of Intravenous Immune Globulin (IVIG)
9
Centers for Medicare & Medicaid Services. 2026 Medicare Parts A and B Premiums and Deductibles
10
Centers for Medicare & Medicaid Services. Final CY 2026 Part D Redesign Program Instructions
11
Centers for Medicare & Medicaid Services. Medicare Prescription Payment Plan
12
Centers for Medicare & Medicaid Services. First Level of Appeal – Redetermination by a Medicare Contractor
13
Centers for Medicare & Medicaid Services. Medicare Appeals